PARP1 and Abnormal retinal morphology: In our study, we selected two approved inhibitors, Olaparib and BMN-673, to facilitate translation into clinical trials for peripherin-2-related retinal diseases, as well as 3-aminobenzamide, previously shown to be a potent PARP inhibitor.